SynchroMed™ III is an implantable drug delivery system that helps manage chronic pain, cancer pain, and severe spasticity.
Medtronic Recalls Pain Drug Infusion Pump Tied to 14 Deaths (2)Michelle Fay Cortez
Pain pumps, also called drug infusion systems, help patients manage pain and symptoms. The pumps are designed to deliver programmed amounts of medication into the patient's body. Medtronic’sSynchroMed™ II intrathecal infusion pumpis a programmable, implantable pump. This product aims to elimina...
This therapy is not for everyone. In addition to risks related to a surgical procedure and drug-related adverse events, pump or catheter problems can cause serious or fatal drug overdose or underdose and may require corrective surgery. Grider JS, Harned ME, Etscheidt MA. Patient selection and...
The company’s pump troubles have not been limited to just insulin pumps. Recently, the LA Times reported that the FDA has filed a court order against Medtronic, severely limiting the making and distributing of the company’s implanted Synchromed II drug pumps, which are often used to treat ...
Department of Neurology, spine and five sense organs - provide surgical equipment including nerve stimulation system, drug infusion system, nerve surgery implantation equipment, surgical auxiliary equipment, diagnosis and treatment system for long-term pain, neurology, urology and gastroenterology, as well...
low-cost combination of drug infusion and electrical stimulation therapy. Such short-term therapy is important for cancer pain management, when life expectancy does not warrant the high cost of a long-term implantable drug infusion pump and another implantable stimulation device, or when direct site...
If insulin, or any liquid, gets inside the tubing connector, it can temporarily block the vents that allow the pump to properly prime the infusion set. This may result in the delivery of too little or too much insulin, which can cause hypoglycemia or hyperglycemia. To prevent liquid from ...
Patients report a reduction in pain scores after receiving targeted drug delivery. 51% of patients completely eliminated other opioids* at 12 months.1 87% of patients rated their quality of life as fair to excellent.2 90% of patients would recommend therapy to a family member or friend.2 ...
In the multibillion-dollar market for diabetes technology, Medtronic’s U.S. diabetes sales have declined in the last four years as the company grappled with regulators and competitors rolled out new devices. With two strokes of a pen in late April, the Food and Drug Administration has given...